rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BEAT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      HeartBeam (BEAT) Q3 2026 Earnings Call Transcript

      Detailed price information for Ferrari N.V. (RACE-N) from The Globe and Mail including charting and trades.

      Nov 13The Globe and MailBEAT
      HeartBeam Inc (BEAT) (Q3 2026) Earnings Call Highlights: FDA Breakthrough Status, ALIGN ACS ...

      HeartBeam Inc (BEAT) advances its 510(k) heart attack detection pathway with strong ALIGN ACS results and extended runway into 2027, while Nasdaq compliance and pivotal study timing remain key risks.

      Nov 13Yahoo FinanceBEAT
      Heartbeam earnings beat by $0.04, revenue fell short of estimates
      Nov 13Investing.comBEAT
      Earnings call transcript: HeartBeam narrows Q3 2026 loss as cash burn eases
      Nov 12Investing.comBEAT
      HeartBeam Reports Third Quarter 2026 Results
      Nov 12Yahoo FinanceBEAT
      HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG

      SANTA CLARA, Calif., November 02, 2026--HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to be as Accurate as Standard 12-Lead ECG

      Nov 2Yahoo FinanceBEAT
      HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026
      Oct 28Yahoo FinanceBEAT
      HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP)
      Oct 26Yahoo FinanceBEAT
      HeartBeam gains FDA acceptance into device acceleration program
      Oct 26Investing.comBEAT
      HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
      Oct 15Yahoo FinanceBEAT
      Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA news
      Oct 6Investing.comBEAT
      Why is Heartbeam stock surging today?
      Oct 5Investing.comBEAT
      HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System - HeartBeam (NASDAQ:BEAT)

      HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.

      Oct 5BenzingaBEAT
      12 Health Care Stocks Moving In Monday's Intraday Session - HeartBeam (NASDAQ:BEAT), PDS Biotechnology (N

      Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology (NASDAQ:PDSB) shares moved

      Oct 5BenzingaBEATPDSB
      HeartBeam stock soars on FDA breakthrough designation
      Oct 5Investing.comBEAT
      HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment

      The designation gives HeartBeam prioritized FDA interaction as it prepares a pivotal study of its 3D ECG technology for assessing suspected heart attacks outside traditional medical settings. Key Investor TakeawaysHeartBeam (NASDAQ:BEAT) received FDA Breakthrough Device Designation for using its 3D ECG technology to assess potential heart attacks at home.

      Oct 5Yahoo FinanceBEAT
      HeartBeam receives FDA breakthrough designation for heart attack tool
      Oct 5Investing.comBEAT
      HeartBeam shifts focus to heart attack detection technology
      Sep 21Investing.comBEAT
      HeartBeam, Inc. Letter to Shareholders

      SANTA CLARA, Calif., September 21, 2026--HeartBeam, Inc. Letter to Shareholders

      Sep 21Yahoo FinanceBEAT

      This is the newest page. Registered accounts read further back.